AstraZeneca has completed the sell-off of another mature product, hiving off its Atacand cardiovascular franchise to Cheplapharm as it continues to slim down and invest in its pipeline.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback